MetaCap

Maravai LifeSciences (MRVI) vs Stoke Therapeutics (STOK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Maravai LifeSciences (MRVI) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 86.1% versus a loss of 8.6%. Over five years, STOK leads with a +6.8% price change compared with -83.2% for MRVI. Maravai LifeSciences is the larger company by market cap ($1.81 billion vs $1.75 billion), about 1.0 times the size, while Stoke Therapeutics is growing revenue faster (+404.5% vs -28.3%).

Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -70.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MRVI+86.13%STOK-8.62%
+148%+58%-33%
Nov 21, 20251 yearNov 20, 2026
MRVI-81.37%STOK-3.56%
+41%-31%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MRVI versus STOK key metrics
MetricMRVISTOK
Share price$6.98$26.81
Market cap$1.81B$1.75B
1-day change-2.92%-0.45%
YTD return+114.77%-15.53%
1-year return+86.13%-8.62%
5-year return-83.18%+6.77%
EPS (TTM)$-0.44$-3.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$185.74M$184.42M
Revenue growth (YoY)-28.34%+404.50%
Net income (latest FY)$-130.77M$-6.88M
Gross margin18.30%—
Operating margin-115.89%-11.16%
Net margin-70.41%-3.73%
52-week high$9.42$40.22
52-week low$2.80$22.05
Distance from 52-week high-25.90%-33.34%
Analyst consensusbuystrong_buy
Avg. price target upside+38.11%+73.00%
Average volume2.72M1.02M
Shares outstanding149.25M65.41M
Employees410170
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRVI has outperformed STOK by 94.8 percentage points over the past year.
  • Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -70.4 cents for Maravai LifeSciences.
  • Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs -28.34%).

About Maravai LifeSciences

MRVI stock →

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.

Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees

About Stoke Therapeutics

STOK stock →

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees

MRVI vs STOK FAQ

Which is bigger, Maravai LifeSciences or Stoke Therapeutics?

Maravai LifeSciences (MRVI) is larger, with a market capitalization of $1.81B compared with $1.75B for Stoke Therapeutics (STOK).

Which stock has performed better over the past year, MRVI or STOK?

MRVI returned +86.13% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.

Are Maravai LifeSciences and Stoke Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons